{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=everolimus+%28RAD%29",
    "query": {
      "intervention": "everolimus (RAD)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 39,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=everolimus+%28RAD%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T08:12:43.785Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01051570",
      "title": "Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "RAD 001",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "MALE",
        "summary": "18 Years to 120 Years · Male only"
      },
      "enrollment_count": 26,
      "start_date": "2010-02",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2020-12-01",
      "last_synced_at": "2026-09-24T08:12:43.785Z",
      "location_count": 4,
      "location_summary": "Evanston, Illinois • Detroit, Michigan • Farmington Hills, Michigan + 1 more",
      "locations": [
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Farmington Hills",
          "state": "Michigan"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01051570"
    },
    {
      "nct_id": "NCT01582191",
      "title": "Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignant Neoplasm",
        "Metastatic Malignant Neoplasm",
        "Recurrent Malignant Neoplasm",
        "Refractory Malignant Neoplasm"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Vandetanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 123,
      "start_date": "2012-05-14",
      "completion_date": "2025-10-22",
      "has_results": true,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-09-24T08:12:43.785Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01582191"
    },
    {
      "nct_id": "NCT01204476",
      "title": "Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastrin-Producing Neuroendocrine Tumor",
        "Lung Carcinoid Tumor",
        "Metastatic Digestive System Neuroendocrine Tumor G1",
        "Pancreatic Glucagonoma",
        "Pancreatic Insulinoma",
        "Pancreatic Polypeptide Tumor",
        "Paraganglioma",
        "Recurrent Digestive System Neuroendocrine Tumor G1",
        "Recurrent Merkel Cell Carcinoma",
        "Recurrent Pancreatic Neuroendocrine Carcinoma",
        "Regional Digestive System Neuroendocrine Tumor G1",
        "Somatostatin-Producing Neuroendocrine Tumor",
        "Stage III Merkel Cell Carcinoma",
        "Stage IV Merkel Cell Carcinoma",
        "Thyroid Gland Medullary Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cixutumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Octreotide Acetate",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2010-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-07-15",
      "last_synced_at": "2026-09-24T08:12:43.785Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01204476"
    },
    {
      "nct_id": "NCT01059318",
      "title": "A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphangioleiomyomatosis"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 24,
      "start_date": "2010-01",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2020-11-19",
      "last_synced_at": "2026-09-24T08:12:43.785Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01059318"
    },
    {
      "nct_id": "NCT04199026",
      "title": "Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metastatic Sarcoma",
        "Recurrent Sarcoma",
        "Resectable Sarcoma"
      ],
      "interventions": [
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Drug Delivery Microdevice",
          "type": "DEVICE"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Ganitumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Pazopanib",
          "type": "DRUG"
        },
        {
          "name": "Polyethylene Glycol",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2025-02-25",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-09-24T08:12:43.785Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04199026"
    },
    {
      "nct_id": "NCT01229943",
      "title": "Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Pancreatic Neuroendocrine Tumor",
        "Locally Advanced Pancreatic Neuroendocrine Tumor",
        "Pancreatic Gastrinoma",
        "Pancreatic Neuroendocrine Tumor G1",
        "Pancreatic Neuroendocrine Tumor G2",
        "Pancreatic Vipoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Octreotide Acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2010-10-15",
      "completion_date": "2018-01-03",
      "has_results": true,
      "last_update_posted_date": "2022-08-04",
      "last_synced_at": "2026-09-24T08:12:43.785Z",
      "location_count": 388,
      "location_summary": "Mobile, Alabama • Anaheim, California • Antioch, California + 272 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Antioch",
          "state": "California"
        },
        {
          "city": "Baldwin Park",
          "state": "California"
        },
        {
          "city": "Bellflower",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01229943"
    },
    {
      "nct_id": "NCT02397083",
      "title": "Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atypical Endometrial Hyperplasia",
        "FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma",
        "FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Levonorgestrel-Releasing Intrauterine System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "DEVICE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 102,
      "start_date": "2015-09-23",
      "completion_date": "2028-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-09-24T08:12:43.785Z",
      "location_count": 18,
      "location_summary": "Greeley, Colorado • Loveland, Colorado • Honolulu, Hawaii + 11 more",
      "locations": [
        {
          "city": "Greeley",
          "state": "Colorado"
        },
        {
          "city": "Loveland",
          "state": "Colorado"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Saginaw",
          "state": "Michigan"
        },
        {
          "city": "Camden",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02397083"
    },
    {
      "nct_id": "NCT00149981",
      "title": "A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Organ Transplantation"
      ],
      "interventions": [
        {
          "name": "everolimus (RAD)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2019-09-09",
      "last_synced_at": "2026-09-24T08:12:43.785Z",
      "location_count": 68,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 51 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00149981"
    },
    {
      "nct_id": "NCT01239342",
      "title": "Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Kidney Carcinoma",
        "Recurrent Renal Cell Carcinoma",
        "Stage III Renal Cell Cancer AJCC v7",
        "Stage IV Renal Cell Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Akt Inhibitor MK2206",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2011-01-27",
      "completion_date": "2018-09-19",
      "has_results": true,
      "last_update_posted_date": "2019-10-10",
      "last_synced_at": "2026-09-24T08:12:43.785Z",
      "location_count": 8,
      "location_summary": "Beverly Hills, California • Duarte, California • Los Angeles, California + 5 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "South Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01239342"
    },
    {
      "nct_id": "NCT00457119",
      "title": "Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "RAD001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "23 Years",
        "maximum_age": "76 Years",
        "sex": "ALL",
        "summary": "23 Years to 76 Years"
      },
      "enrollment_count": 69,
      "start_date": "2007-02",
      "completion_date": "2009-11",
      "has_results": false,
      "last_update_posted_date": "2013-02-12",
      "last_synced_at": "2026-09-24T08:12:43.785Z",
      "location_count": 4,
      "location_summary": "Washington D.C., District of Columbia • New Orleans, Louisiana • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00457119"
    }
  ]
}